Varespladib(LY315920,LY-333013) C13850

中文版 | English

Pharmacology: Transporters; Nuclear Receptors; Ion Channels; 7-TM Receptors; Aurora Kinase Inhibitors; Activators; Cell Cycle/Checkpoint; CETP inhibitor; PI3K/Akt/mTOR; Angiogenesis/Tyrosine Kinase; HDAC; Cytochrome P450; Apoptosis; Proteases/HSP90/HSP70; Wnt/Hedgehog/Notch; Other Pharmacology

Research Area: Immunology; Infection; Cardiovascular Disease; Antivirals; Cancer

Product Type: Peptides; Natural Compounds

Product Information

Home >>> Product Class >>> Pharmacology >>> Other Pharmacology >>> sPLA2

C13850 Varespladib(LY315920,LY-333013)

Synonyms：LY-315920, LY-333013

CAS No.：172732-68-2

Molecular Formula：C21H20N2O5

Molecular Weight：380.40

Solubility：Soluble in DMSO

Appearance：White powder

Purity：>99%

Pakage：5mg,10mg,20mg

Storage：at -20℃ 2 years

Varespladib(LY315920,LY-333013) Introduction：

Chemical Name: [[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid

Varespladib is a selective inhibitor of human, group IIA, nonpancreatic secretory PLA2 (sPLA2). In a chromogenic isolated enzyme assay, Varespladib inhibited sPLA2 activity with an IC50 of 9 6 ±1 nM or 7.3 *10-6 mole fraction, which approached the stiochiometric limit of this assay.Varespladib was 40-fold less active against human, group IB, pancreatic sPLA2 and was inactive against cytosolic PLA2 and the constitutive and inducible forms of cyclooxygenase.Human sPLA2-induced release of thromboxane A2 (TXA2) from isolated guinea pig lung bronchoalveolar lavage cells was inhibited by Varespladib with an IC50 of 0.79 nM. Therefore£¬the use of Varespladib have a beneficial effect in preventing various inflammatory disease states.